BCM
REGN icon

Brasada Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brasada Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-30
Closed -$11K – 237
2018
Q4 		$11K Buy
+30
New +$11K ﹤0.01% 229
2018
Q1 		– Sell
-40
Closed -$15K – 305
2017
Q4 		$15K Buy
+40
New +$16.2K 0.01% 226

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brasada Capital Management's REGN Position: Q1 2019 in Review

Brasada Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 30 shares — an estimated $11K sold.

Brasada Capital Management first reported a position in REGN in Q4 2017 and held it in 2 quarters. The position peaked at $15K in Q4 2017. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • Brasada Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Brasada Capital Management sold 30 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $11K.
  • Brasada Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Brasada Capital Management's Regeneron Pharmaceuticals position peaked at $15K in Q4 2017.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Brasada Capital Management's 13F filing for Q1 2019, filed 6 May 2019.